Welchol as Monotherapy for Type 2 Diabetes Mellitus

Completed · Phase 3 · Has a placebo group

Conditions studied: Type 2 Diabetes Mellitus

In brief

The current study investigates Welchol as monotherapy to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with diet and exercise alone. The study will evaluate if Welchol monotherapy for Type 2 Diabetes Mellitus will be safe, well tolerated and efficacious.

Key facts

Study ID

NCT00789737

Run by

Daiichi Sankyo

People needed

357

Starts

2009-01-01

Expected to finish

2011-12-01

Last updated by the study team

2014-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects >= 18 years of age;
• Women of childbearing potential (WOCBP) must be using an adequate method of contraception as detailed in the protocol.
• Diagnosis of Type 2 Diabetes Mellitus;
• HbA1C >= 7.5% and =< 9.5 % at screening;
• Fasting C-peptide >0.5 ng/mL at screening;
• Drug naïve (no prior treatment with OAD) or having received no pharmacologic therapy for diabetes for the 3 month period prior to screening;
• Clinically stable in regards to medical conditions other than type 2 diabetes;
• Concomitant medications must be at stable doses for at least 30 days prior to enrollment, and are not anticipated to need adjustment during the study period; and
• Fasting glucose =< 240 mg/dL at randomization

You may not qualify if…

• A history of type 1 diabetes and/or a history of ketoacidosis;
• History of bowel obstruction;
• History of hypertriglyceridemia-induced pancreatitis;
• Fasting serum triglyceride concentrations >500 mg/dL;
• History of dysphagia, swallowing disorders, gastroparesis, other gastrointestinal (GI) motility disorders, or major GI surgery;
• History of insulin use of >= 2 weeks duration in the previous 3 months or a total of > 2 months of insulin therapy at any time prior to screening;
• Two or more fasting self-monitored blood glucose (SMBG) levels >240 mg/dL during the placebo lead-in period.
• Previous treatment with a bile acid sequestrant, including Welchol within the 3 months prior to screening;
• Body mass index (BMI) >40 kg/m2;
• Weight loss > 3% in prior 3 months; and
• LDL <60 mg/dL.

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Montgomery, Alabama, United States
• Study site — Muscle Shoals, Alabama, United States
• Study site — Green Valley, Arizona, United States
• Study site — Mesa, Arizona, United States
• Study site — Mesa, Arizona, United States
• Study site — Tucson, Arizona, United States
• Study site — Tucson, Arizona, United States
• Study site — Tucson, Arizona, United States
• Study site — Searcy, Arkansas, United States
• Study site — Buena Park, California, United States
• Study site — Burbank, California, United States
• Study site — Chula Vista, California, United States
• Study site — Garden Grove, California, United States
• Study site — Huntington Park, California, United States
• Study site — Irvine, California, United States
• Study site — La Mirada, California, United States
• Study site — Lincoln, California, United States
• Study site — Lomita, California, United States
• Study site — Los Angeles, California, United States
• Study site — Los Angeles, California, United States
• Study site — Los Gatos, California, United States
• Study site — Santa Ana, California, United States
• Study site — Tustin, California, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.